title: COPD Exacerbation and Cholinesterase Therapy in Dementia Patients.
abstract: BACKGROUND
  Chronic obstructive pulmonary disease (COPD) is a nonreversible inflammatory condition of the lungs. Acetylcholine is a neurotransmitter involved in autonomic regulation of the airways, resulting in bronchoconstriction and mucous production. Cholinesterase inhibitors (ChEIs), a cornerstone therapy of dementia treatment, increase acetylcholine. Theoretically, ChEI use in patients with COPD can place patients at increased risk of exacerbation secondary to increased acetylcholine activity.
  
  
  METHODS
  A retrospective chart review was performed comparing veterans with dementia and COPD who received ChEIs with those who did not at the Veterans Affairs North Texas Health Care System. Frequency of exacerbation in the first 90 days following ChEI initiation was compared. Secondary outcomes assessed exacerbation severity and a potential protective effect of inhaled anticholinergics.
  
  
  RESULTS
  A total of 94 patients were eligible for the study; 52 received a ChEI and 42 did not. The risk of exacerbation over 90 days was higher in the ChEI users with 10 (19%) experiencing an exacerbation compared with 3 (7%) in the nonusers (P = 0.133), showing a clinically significant trend. Of the patients experiencing an exacerbation, 2 patients on ChEIs had multiple exacerbations over the 90 days. The use of inhaled anticholinergics was not found to decrease the risk of exacerbation.
  
  
  CONCLUSIONS
  The use of ChEIs may increase the risk of COPD exacerbation in the first 90 days of therapy in patients with dementia and COPD. This finding is clinically significant as previous studies have indicated no risk.
authors.affiliation: Division of Geriatrics, Texas Tech University (TTU) Health Sciences Center, School of Pharmacy, Abilene, Texas, USA.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Mahan
authors.forename: Amie Taggart
authors.initials: AT
authors.lastname: Blaszczyk
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000280:Administration, Inhalation; D000368:Aged; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000503:physiopathology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013781:Texas; D013997:Time Factors; D014481:United States; D014493:United States Department of Veterans Affairs; D014728:Veterans
chemical_list: D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D000109:Acetylcholine